June 6 (Reuters) – The U.S. Food and Drug Administration on Tuesday approved Cue Health’s (HLTH.O) at-home COVID-19 test, the first coronavirus test to get marketing authorization using a traditional premarket review, the agency said.
The FDA said this was the first ever at-home test authorized using the traditional review process for any respiratory illness.
“This is part of the FDA’s broader effort to advance the development and availability of at-home tests for a variety of medical conditions to expand patient access to testing,” FDA official Jeff Shuren said in a statement.
Reporting by Raghav Mahobe in Bengaluru; Editing by Krishna Chandra Eluri
Our Standards: The Thomson Reuters Trust Principles.